Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

MRCP(UK), FRCP(Edin), FRCP(Lond), FRCPCH(UK), FSLCPaed, FCCP, Hony. FRCPCH(UK), Hony. FCGP(SL) Specialist Consultant Paediatrician and Honorary Senior Fellow, Postgraduate Institute of Medicine, ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 ...

Sino Biopharmaceutical Limited, or Sino Biopharm, expects to have approximately five innovative products approved in China ...

MGNX earnings call for the period ending December 31, 2024. MacroGenics ( MGNX -2.75%) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Vaping among students has become a growing concern worldwide, and the UAE is taking decisive action to curb this trend.

Evacuating the Tahoe basin in summer could take 14 hours, and 99% of properties are at risk — yet new resorts are being built in high-danger fire areas.